Why the study?
Does left ventricular assist device implantation alter metabolic and inflammatory gene expression in end-stage heart failure patients?
Observational
Does left ventricular assist device implantation alter metabolic and inflammatory gene expression in end-stage heart failure patients?
LVAD therapy in end-stage heart failure induces a common gene expression signature related to metabolic plasticity, inflammation reduction, and repair, contributing to cardiac homeostasis.
Left ventricular assist devices remain a major step forward for end-stage heart failure patients awaiting transplantation. We investigated the molecular basis of the longitudinal effect of left ventricular assist device implantation in both ischemic and nonischemic cardiomyopathy patients. The results revealed a common signature of 13 genes associated with glucocorticoid receptor overexpression pretransplantation, independent of the etiology. Four key molecular hub genes from this signature were highlighted, involved respectively in metabolic plasticity (PDK4), limited inflammation (FKBP5 and ZBTB16), and repair (FOXO3). It shows, however, that these pathways contribute to cardiac homeostasis.
No takes yet. Share an insight, caveat, or question.
Mury et al. (2026) conducted an observational in End-stage heart failure. Left ventricular assist device (LVAD) implantation was evaluated on Molecular basis of the longitudinal effect of LVAD implantation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: